The Efficacy of 10-day or 14-day Course of Bismuth-containing Quadruple Therapy:A Randomized Clinical Trial

NCT05586113 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

398

Enrollment

OTHER

Sponsor class

Conditions

Helicobacter Pylori Infection

Interventions

DRUG: 10-day Tegoprazan bismuth-containing quadruple therapy

Sponsor

Shandong University

Collaborators

[object Object]
[object Object]